VivoSim Labs, INC. IPO - What You Need to Know

Thinking about the VivoSim Labs IPO? It is exciting to get in early, but before you invest, let’s break down what this company actually does and the risks involved.

1. What does this company do?

Think of VivoSim Labs as "architects of digital biology." They use 3D human tissue models—specifically liver and intestine—to help drug companies test if new medicines are safe before human trials.

They recently rebranded from "Organovo" to "VivoSim Labs" to shift from developing their own drugs to a service-based model. They now offer research services to pharmaceutical partners using their liver testing platform. They claim this platform is top-tier, having correctly identified 87.5% of known liver-toxic drugs in recent tests. They are also developing an internal drug for inflammatory bowel disease, aiming for FDA review by December 2026.

2. How do they make money?

VivoSim earns money through service contracts. Pharmaceutical companies pay fees to use VivoSim’s testing platforms for their own safety assessments. To boost their cash, they also sold an older drug program for $10 million upfront, with another $50 million possible if they hit specific clinical and regulatory goals.

3. What’s the deal with this offering?

This is a "best efforts" offering. The underwriter does not have to buy unsold shares, and there is no minimum amount of money the company must raise to close the deal.

• The Package: You are buying units. Each unit includes one share of stock and 1.5 warrants.
• What are Warrants? These give you the right to buy more shares later at a set price.
• The "Cashless" Trap: The company expects these warrants to be exercised on a "cashless" basis. The company gets no cash from this. Instead, they issue more shares to the warrant holder based on the stock price. This creates more shares, which reduces your ownership percentage without bringing new money into the company.

4. What are the main risks?

• The "Share Printing" Problem: The warrant structure creates a high risk of dilution. If the stock price drops, the company might have to issue over 720 million new shares. They currently only have 196 million shares authorized, so they would need shareholder approval to issue more, which could cause major business disruptions.
• Going Concern: Auditors have issued a "going concern" warning. This means they doubt the company can stay in business. Current cash will only last until July 2026, so they will need to raise more money soon.
• No Safety Net: Because there is no minimum fundraising goal, the company might raise very little money. You cannot get a refund if they fail to meet their goals.
• Nasdaq Listing Risk: The company is under a "Mandatory Panel Monitor" until April 2026 due to past rule violations. If they fail to meet Nasdaq standards again, they could be delisted, making it very difficult to sell your shares.

5. The Bottom Line

VivoSim Labs trades as VIVS on the Nasdaq. This is a high-risk, speculative investment. Between the "going concern" warning, the risk of massive share dilution, and the threat of delisting, this is a volatile opportunity.

Before you commit:

• Read the Prospectus: Always look at the official SEC filing. It contains the fine print that can make or break your decision.
• Check the "Risk Factors": Every prospectus has a section dedicated to risks—read it carefully.
• Consider your goals: If you aren't comfortable with the possibility of losing your entire investment, this may not be the right fit for your portfolio.

Disclaimer: I am an AI, not a financial advisor. This offering involves complex risks. Never invest money you cannot afford to lose.